mRNA Vaccines in Glioma: Antigen Selection, Immune Profiling, Comprehensive Strategies and Challenges

Fan Yang

doi:10.62051/dgf2a481

Authors

Fan Yang

DOI:

https://doi.org/10.62051/dgf2a481

Keywords:

mRNA vaccine, glioma, tumor microenvironment, tumor antigens, immune subtypes.

Abstract

Glioma is one of the most invasive primary brain tumors, and the exploration of its treatment strategies has always been a focus in the field of neurooncology. In recent years, mRNA vaccine technology has shown great potential in the COVID-19 epidemic, and its application in the treatment of glioma has also attracted increasing attention. This article reviews the research progress of mRNA vaccines in the treatment of glioma, including the advantages and challenges of mRNA vaccines, the comparison of different RNA therapy methods, as well as the screening of tumor specific antigens, differentiation of immune subtypes, and development of comprehensive treatment strategies. Although mRNA vaccines have shown promising prospects in the treatment of gliomas, their clinical translation still faces challenges such as safety, production scale, and cost-effectiveness. The author believes that a deep understanding of the molecular mechanisms of glioma and the heterogeneity of the immune microenvironment is crucial for developing effective mRNA vaccines. Future research needs to make breakthroughs in improving the stability of mRNA vaccines, optimizing immunogenicity, developing personalized vaccines, and comprehensive treatment strategies.

Downloads

Download data is not yet available.

References

[1] Dain, L., Zhu, G. Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment. International Journal of Pharmaceutics, 2023, 638: 122924.

[2] Ye, L., et al. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development. Journal of Translational Medicine, 2021, 19: 352.

[3] Ma, S., et al. Recognition of tumor-associated antigens and immune subtypes in glioma for mRNA vaccine development. Frontiers in Immunology, 2021, 12: 738435.

[4] Zhou, Q., et al. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma. Theranostics, 2021, 11: 9775-9790.

[5] Trivedi, V., et al. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors. Genome Medicine, 2024, 16: 17.

[6] Wu, C., et al. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. Journal of Big Data, 2022, 9: 92.

[7] Chen, J., et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119: e2207841119.

[8] Zhang, C., Zhang, B. RNA therapeutics: updates and future potential. Science China. Life Sciences, 2023, 66: 12-30.

[9] Iavarone, C., O'Hagan, D. T., Yu, D., Delahaye, N. F., Ulmer, J. B. Mechanism of action of mRNA-based vaccines. Expert Review of Vaccines, 2017, 16: 871-881.

[10] Seagle, B. L., et al. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6: 18641-18652.

[11] Tian, W., et al. Recent advances of IDH1 mutant inhibitor in cancer therapy. Frontiers in Pharmacology, 2022, 13: 982424.

[12] Wei, Y., et al. The complement C3-C3aR pathway mediates microglia-astrocyte interaction following status epilepticus. Glia, 2021, 69: 1155-1169.

[13] Labreche, K., et al. TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications, 2015, 6: 7207.

[14] Peng, F. W., Liu, D. K., Zhang, Q. W., Xu, Y. G., Shi, L. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opinion on Therapeutic Patents, 2017, 27: 987-1004.

[15] Lin, H., et al. Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development. Frontiers in Immunology, 2022, 13: 773264.

[16] Wang, C., Zhang, Y., Dong, Y. Lipid nanoparticle-mRNA formulations for therapeutic applications. Accounts of Chemical Research, 2021, 54: 4283-4293.

[17] Segura-Collar, B., et al. Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators. Acta Neuropathologica Communications, 2023, 11: 79.

[18] Cao, Q., Fang, H., Tian, H. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo. Biomaterials, 2024, 310: 122628.

[19] Kang, Z., Tang, M. Progress and analysis on the development of 2019-nCoV vaccine. Journal of Biomedical Engineering, 2020, 37: 373-379.

[20] Zong, Y., Lin, Y., Wei, T., Cheng, Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Advanced Materials, 2023, 35: e2303261.

[21] Chaudhary, N., Weissman, D., Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews. Drug Discovery, 2021, 20: 817-838.

[22] Meng, Z., Ma, D. Research progress on mRNA vaccines and their mechanism of action. Chinese Journal of Biological Products, 2021, 34: 740-744.

[23] Meng, W., Peng, X. Current status, challenges, and prospects of cancer mRNA vaccines. Practical Oncology Journal, 2023, 38: 218-221.

[24] Baden, L. R., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 2021, 384: 403-416.